Project Grant R61NS127271
Award Date
9/11/23
Completion Date
8/31/25
Dollars Obligated
$1.5M
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40506, USA
Similar Awards
This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...
This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...
The University of North Carolina at Chapel Hill was awarded a $9,275,866 Cooperative Agreement by the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279). The purpose of the award is to develop small molecule drugs that engage a specific G protein-coupled receptor (GPCR) in the amygdala, which could provide a safer alternative to opioid-based pain relief by reducing the unpleasant perception of pain without the...
This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $118,457 to The Trustees of the University of Pennsylvania to conduct research aimed at harnessing the genetics of chronic pain to inform the development of non-addictive analgesic medications. The 4-year project, starting on April 15, 2025, will characterize the genetic architecture underlying chronic pain liability and addiction, estimate...
This Project Grant award of $650,079 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to develop selective probes targeting the α9 nicotinic acetylcholine receptor (α9*-nAChR) for treating chronic inflammatory and neuropathic pain. The key objectives are to: 1) Develop small-molecule agonists and antagonists of α9*-nAChR through structure-activity...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $400,000 Project Grant to Navega Therapeutics, Inc., a San Diego-based biotechnology company, under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding will support Navega's research and development efforts to advance novel epigenetic gene therapies targeting the voltage-gated sodium channel NAV1.7 for the treatment of chronic pain. This innovative approach aims to transiently repress NAV1.7...
This $675,107 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders supports research by Northeastern University to develop novel non-opioid, non-addictive analgesics for treating neuropathic pain. The key objectives are to: 1) design and synthesize new cannabinoid CB1 receptor allosteric agonist-positive allosteric modulator (CB1R AGO-PAM) and CB2 receptor...
This Project Grant award, with a total funding amount of $664,772, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The award supports research to investigate the signaling mechanisms involving the neurotensin receptor 2 (NTSR2) and voltage-gated calcium channels (Cav2.3 and Cav2.2) as a novel, non-opioid analgesic pathway for the...
This Project Grant award of $2,068,842 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to identify how pain influences the activity of prefrontal cortical dynorphin neurons and their role in modulating nociception and maladaptive affective behaviors. The research aims to dissect the mechanisms by which dynorphin neurons and release of dynorphin neuropeptides or fast neurotransmitters...